Upregulation of microRNA‑1 inhibits proliferation and metastasis of breast cancer

Peng,Jing; Yuan,Chenwei; Wu,Ziping; Wang,Yan; Yin,Wenjin; Lin,Yanping; Zhou,Liheng; Lu,Jinsong

doi:10.3892/mmr.2020.11111

Upregulation of microRNA‑1 inhibits proliferation and metastasis of breast cancer

Authors:
- Jing Peng
- Chenwei Yuan
- Ziping Wu
- Yan Wang
- Wenjin Yin
- Yanping Lin
- Liheng Zhou
- Jinsong Lu
View Affiliations

Affiliations: Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, P.R. China
Published online on: May 4, 2020 https://doi.org/10.3892/mmr.2020.11111
Pages: 454-464
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have shown that microRNAs (miRs) play a key role in the regulation of cancer development. In the present study, reverse transcription‑quantitative PCR was used to detect the expression of miR‑1 in breast cancer and adjacent tissues, and survival analysis was performed to compare the low‑expression groups with the Kaplan-Meier method. Overexpression of miR‑1 was used to observe the effects on the proliferation, migration and invasion of breast cancer cells in vitro and in vivo. Moreover, Bcl‑2 expression was measured by western blotting and luciferase assays after the overexpression of miR‑1. The present study reported that miR‑1 is expressed at low levels in breast cancer and that cell proliferation, migration and invasion are inhibited in miR‑1‑overexpressing cells. Enhanced miR‑1 expression can also increase cell apoptosis. The present study also demonstrated that Bcl‑2 is a potential target of miR‑1. In vivo studies indicate that overexpression of miR‑1 decreases tumor volume and weight in nude mice. The data from the present study demonstrated for the first time that overexpression of miR‑1 increases the sensitivity of breast cancer cells to paclitaxel and cisplatin. The present study provided new evidence for the important role of miR‑1 in the tumorigenesis and drug sensitivity of breast cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Minemura H, Takagi K, Miki Y, Shibahara Y, Nakagawa S, Ebata A, Watanabe M, Ishida T, Sasano H and Suzuki T: Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor. Cancer Sci. 106:1642–1650. 2015. View Article : Google Scholar : PubMed/NCBI
3	Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G and Puglisi F: Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis. 32:125–133. 2015. View Article : Google Scholar : PubMed/NCBI
4	Higgins MJ and Baselga J: Targeted therapies for breast cancer. J Clin Invest. 121:3797–3803. 2011. View Article : Google Scholar : PubMed/NCBI
5	Ali S and Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2:101–112. 2002. View Article : Google Scholar : PubMed/NCBI
6	Piao HL and Ma L: Non-coding RNAs as regulators of mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 17:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
7	Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114. 2008. View Article : Google Scholar : PubMed/NCBI
8	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
9	Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL and Massague J: Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
10	Nohata N, Hanazawa T, Enokida H and Seki N: microRNA-1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers. Oncotarget. 3:9–21. 2012. View Article : Google Scholar : PubMed/NCBI
11	Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, et al: MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 40:3689–3703. 2012. View Article : Google Scholar : PubMed/NCBI
12	Liu C, Zhang S, Wang Q and Zhang X: Tumor suppressor miR-1 inhibits tumor growth and metastasis by simultaneously targeting multiple genes. Oncotarget. 8:42043–42060. 2017. View Article : Google Scholar : PubMed/NCBI
13	Liu T, Hu K, Zhao Z, Chen G, Ou X, Zhang H, Zhang X, Wei X, Wang D, Cui M and Liu C: MicroRNA down-regulates proliferation and migration of breast cancer stem cells by inhibiting the Wnt/β-catenin pathway. Oncotarget. 6:41638–41649. 2015. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Lu J, Zhao FP, Peng ZL, Zhang MM, Lin SX, Liang BJ, Zhang B, Liu X, Wang L, Li G, et al: EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma. Oncotarget. 5:11319–11332. 2014. View Article : Google Scholar : PubMed/NCBI
16	Sheng JY, Shi BL and Chen HF: Establishment and appraisal of DDP resistant variant of triple negative breast cancer cell line MDA-MB-231. Cancer Res Prev Treat. 43:175–180. 2016.
17	Cancer Genome Atlas Network, . Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
18	Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, et al: Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 68:5049–5058. 2008. View Article : Google Scholar : PubMed/NCBI
19	Chang YS, Chen WY, Yin JJ, Sheppard-Tillman H, Huang J and Liu YN: EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Res. 75:3077–3086. 2015. View Article : Google Scholar : PubMed/NCBI
20	Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI
21	Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K: Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI
22	Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa M: The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011. View Article : Google Scholar : PubMed/NCBI
23	Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, Qu J and Tu L: MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem. 284:29596–29604. 2009. View Article : Google Scholar : PubMed/NCBI
24	Cory S, Huang DC and Adams JM: The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene. 22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
25	Tang Y, Zheng J, Sun Y, Wu Z, Liu Z and Huang G: MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J. 50:377–387. 2009. View Article : Google Scholar : PubMed/NCBI
26	Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, Blagosklonny MV and McCubrey JA: Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res. 9:1161–1170. 2003.PubMed/NCBI
27	Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, et al: MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 285:21496–21507. 2010. View Article : Google Scholar : PubMed/NCBI
28	Duan Z, Lamendola DE, Duan Y, Yusuf RZ and Seiden MV: Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol. 55:277–285. 2005. View Article : Google Scholar : PubMed/NCBI
29	Zhou L, Xu S, Yin W, Lin Y, Du Y, Jiang Y, Wang Y, Zhang J, Wu Z and Lu J: Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: A prospective, single arm, phase II study. Oncotarget. 8:79305–79314. 2017. View Article : Google Scholar : PubMed/NCBI
30	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
31	Hua L, Zhu G and Wei J: MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy. Cell Biol Int. 42:1240–1249. 2018. View Article : Google Scholar : PubMed/NCBI